Last reviewed · How we verify
NCT05521932
Establishment and Application of Endometrial 3D-organoid in Endometrial Injury Repair
trial testing endometrium collected in Asherman Syndrome in 6 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Women's Hospital School Of Medicine Zhejiang University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6 |
| Start date | 20 September 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- endometrium collected
Conditions studied
- Asherman Syndrome — all drugs for Asherman Syndrome →
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Who can join
Adults 18 to 45, female only, with Asherman Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Normal endometrial repair occurs without scar formation; however, in some women, these normal repair mechanisms are aberrant, resulting in intrauterine adhesion (IUA) formation. Intrauterine adhesion (IUA) is one of the common causes of secondary infertility, accounting for approximately 8% of disease etiologies while the pathogenesis of IUA remains unclear. Organoids derived from IUA endometrium can be used as excellent models to study IUA due to genetically stable passage and the characteristics of simulating the microenvironment of the uterine cavity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
Verify or expand the search:
- PubMed search for NCT05521932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asherman Syndrome
Currently open trials in the same condition.
- NCT04671914 — Prevalence of Intrauterine Adhesions After D&C With or Without Antiadhesion Gel After Abortion in Second Trimester. · Phase 4 · recruiting
Other Women's Hospital School Of Medicine Zhejiang University trials
Trials by the same sponsor.
- NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
- NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
- NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
- NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
- NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05521932 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05521932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing